Stem Cells in Aesthetics: What the Evidence Says

How claims are graded here

Every claim on this site sits in one of four groups, and the group matters more than the wording. Established means the claim follows from evidence that is consistent and is reflected in how the treatment is approved and used: that transplantation treats defined blood and immune diseases, that a fat graft behaves as a graft, and that a plant extract in a jar is a cosmetic all belong here. Limited means there is real evidence but it is narrow, or it applies to one product rather than to a category, so a finding about one does not carry to the rest. Emerging means the mechanism is plausible and early work points one way, but the study that would settle the question has not been done. Not supported means the claim is made confidently and the evidence does not carry it. Two rules keep the grading honest. The first is that a grade belongs to a specific thing and not to a word, because fat, blood products, plant extracts, culture media and living cells are separate product classes with separate rules. The second is that evidence and regulatory status are graded in separate columns, because a product can be lawful to prepare and supply while never having been approved for the use it is sold for. Where the two disagree, both are reported rather than averaged.

What is approved, and what is not

Transplantation sits on the medicine side of the line. It has named indications, a characterised cell product, a laboratory release process and a body of controlled evidence that a regulator has assessed, and none of that is in dispute. The cosmetic products are on the other side. A product can be regulated as a medicine, as a biological product, or as a tissue and cell preparation, and the third route was written for transfers that happen in a hospital between a donor and a patient for a clinical reason. A preparation made from a patient's own tissue and injected for a cosmetic purpose fits neither that picture nor the medicine picture, and it is often described as minimally manipulated and for same day use, which is the language that keeps it outside the medicine pathway. What it then lacks is the thing that pathway provides: an assessment that the product does what is claimed for the use it is being sold for. Several regulators have issued statements that cell products offered for cosmetic use are unapproved, and the position varies by market. A separate point concerns fat grafting, which is regulated as a tissue transfer and behaves as a graft. The stem cell label attached to it is not a regulatory category and does not change the route it sits on. Lawful and approved are different words, and only the second one means that somebody has examined whether the thing works.

What the risks and limits actually are

The harm profile of an unapproved cell injection is documented rather than speculative, and it follows from what the products are. Any material injected into the body has to be sterile, and sterility has to be assured by a validated process rather than by care; a preparation made at the point of care has no such process behind it. Reported consequences include infection at the injection site, collections of pus requiring drainage, and in the most serious cases infection that spread beyond the treated area. The body can also respond to what was placed in it, with prolonged swelling and redness, firmness and nodules that do not settle, and granuloma formation, in which the tissue builds a persistent inflammatory mass around material it cannot clear. This is where the reversibility question bites. A complication from a reversible filler can sometimes be addressed by dissolving it, and in this area there is usually no equivalent option: what was injected often cannot be identified with certainty, cannot be dissolved and cannot be removed except by surgery. A further limit is on knowledge rather than on tissue. These preparations are not characterised, they are not followed in a register, and there is often no record of what was in the syringe, so an unusual outcome cannot be linked to a product and a safety signal that a regulated system would detect may never be seen. Absence of reported harm is not the same as absence of harm, particularly when no system is doing the reporting.

The options that have an evidence base

Doing nothing is an option and it belongs first, because the decision here is usually one that cannot be undone, and a treatment that cannot be reversed deserves more time than one that can. Where a change is wanted, the options with an evidence base come before the ones without. A hyaluronic acid filler restores volume and can be dissolved if the result is not wanted or if a complication occurs, which makes it a way of seeing how a change feels before committing to a permanent one. Its limits are equally real: it is temporary, it does not amount to a cell treatment, and repeated treatment is an ongoing commitment rather than a course with an end. Fat grafting is an established operation for volume and contour, with a defined regulatory position, an unpredictable rate of survival and its own donor site. Energy-based treatments and topical approaches act on the surface, their effects are modest, and they can be stopped. Where the concern is loose skin rather than volume, an operation addresses it mechanically, and no injectable preparation is a smaller version of one. Where the concern is a blood or immune condition, transplantation is the established treatment and the decision belongs in a hospital. Which of these applies is an individual clinical question, and this review does not answer it for anyone.

How this review is kept current

This subject moves on two clocks, and the faster one is marketing. Regulation and evidence accumulate slowly, because an authorisation or a trial is a deliberate process with an end point. Marketing moves much faster: a product is launched with a cell claim attached, the claim is repeated until it sounds like a finding, and the studies that would test it are not run because the claim is already working. The gap between the two is the subject of this site, so this review is dated and revisited on a short cycle, and it covers three things. The first is whether a claim has moved between the four grading groups, in either direction, because a claim can become supported as well as cease to be. The second is regulatory status, since a statement that a product is unapproved for cosmetic use is a checkable fact and can change. The third is whether the evidence base has changed in kind, because another laboratory observation is a different event from a randomised trial that measures a change in people, and only the second can settle the question this category answers in advance. Where this review is wrong, the correction is made to the page rather than noted elsewhere, and the date of the most recent review is shown on every page.

Related guides